Equibles does not estimate personal net worth.
Get an email with a short summary when NewAmsterdam Pharma Co N.V. publishes a filing, an earnings call transcript or a press release.
Get NAMS alertsMichael Davidson is recorded as CEO at NewAmsterdam Pharma Co N.V. (NAMS). The newest filing on record that lists Michael Davidson as CEO at NewAmsterdam Pharma Co N.V. (NAMS) is dated May 6, 2026. The proxy statement of NewAmsterdam Pharma Co N.V. reports total compensation of $5,832,558 for Michael Davidson in fiscal 2023, including a base salary of $569,000. Michael Davidson has spoken on 2 earnings calls and 2 other investor events across 1 company, most recently for NewAmsterdam Pharma Co N.V. on June 9, 2026. NewAmsterdam Pharma Co N.V. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at NewAmsterdam Pharma Co N.V. includes Willian H. Lewis, J.D., M.B.A. (Chairman), Ian Somaiya (CFO), Robert W. Gunning (Chief Accounting Officer) and 3 others.
“We've had a really productive year, you know, firing on all cylinders. I mean, all our trials are rolling along on schedule or ahead of schedule.”
“So first and foremost about ovacetrapib that I think is not really appreciated as much as it should is how well-tolerated and no difference in the side effect profile of placebo in our phase 3 trials.”
“We've had a really productive year, you know, firing on all cylinders. I mean, all our trials are rolling along on schedule or ahead of schedule.”
“We've had a really productive year, you know, firing on all cylinders. I mean, all our trials are rolling along on schedule or ahead of schedule.”
Start not stated–present
Last confirmed May 6, 2026
Biotechnology · Healthcare
CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Executive Officer | $569,000 | $5,832,558 |
